Kezar Life Sciences (NASDAQ:KZR) Trading Down 6.2%

Kezar Life Sciences, Inc. (NASDAQ:KZR - Get Free Report)'s stock price was down 6.2% during mid-day trading on Monday . The stock traded as low as $0.80 and last traded at $0.81. Approximately 578,223 shares changed hands during trading, a decline of 19% from the average daily volume of 710,630 shares. The stock had previously closed at $0.86.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a "buy" rating and issued a $20.00 target price on shares of Kezar Life Sciences in a research note on Friday, March 15th.

Kezar Life Sciences Trading Down 6.2 %

The stock's 50 day simple moving average is $0.90 and its 200 day simple moving average is $0.89. The firm has a market cap of $58.93 million, a PE ratio of -0.57 and a beta of 0.47. The company has a debt-to-equity ratio of 0.05, a quick ratio of 11.66 and a current ratio of 11.66.

Kezar Life Sciences (NASDAQ:KZR - Get Free Report) last posted its quarterly earnings data on Thursday, March 14th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.39) by $0.04. On average, sell-side analysts forecast that Kezar Life Sciences, Inc. will post -1.26 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Kezar Life Sciences

A number of hedge funds and other institutional investors have recently modified their holdings of KZR. BlackRock Inc. raised its holdings in Kezar Life Sciences by 14.2% during the 2nd quarter. BlackRock Inc. now owns 5,089,147 shares of the company's stock valued at $12,468,000 after buying an additional 631,157 shares during the last quarter. State Street Corp raised its stake in shares of Kezar Life Sciences by 381.3% during the third quarter. State Street Corp now owns 3,537,701 shares of the company's stock valued at $30,460,000 after acquiring an additional 2,802,611 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Kezar Life Sciences by 0.8% during the fourth quarter. Vanguard Group Inc. now owns 3,063,484 shares of the company's stock valued at $2,902,000 after acquiring an additional 22,917 shares during the last quarter. Granahan Investment Management LLC boosted its holdings in shares of Kezar Life Sciences by 31.2% during the fourth quarter. Granahan Investment Management LLC now owns 1,906,175 shares of the company's stock worth $1,806,000 after purchasing an additional 453,617 shares during the period. Finally, Sphera Funds Management LTD. grew its stake in shares of Kezar Life Sciences by 44.7% in the first quarter. Sphera Funds Management LTD. now owns 1,888,228 shares of the company's stock worth $5,910,000 after purchasing an additional 583,045 shares during the last quarter. Institutional investors own 67.90% of the company's stock.

About Kezar Life Sciences

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.